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Background: The aim of this study was to elucidate the mechanisms responsible for the location of B-cell non-
Hodgkin’s lymphoma (B-NHL) at different anatomical sites. We speculated that the malignant B cells in these
disorders have the potential for trafficking between blood and secondary lymphoid organs (SLO) or extranodal
sites and that their preferential accumulation at different locations is governed by the expression of key molecules
that regulate the trafficking of normal lymphocytes.
Methods: Biopsy or blood samples from 91 cases of B-NHL affecting SLO (n = 27), ocular adnexae (n = 51) or blood
(n = 13) were analysed by immunohistochemistry or flow cytometry for the expression of the following molecules:
CCR7, CCL21 and αL (required for the entry of normal lymphocytes into SLO); CXCR4, CXCL12 and α4 (required for
entry into extranodal sites); CXCR5, CXCL13 and S1PR2 (required for tissue retention); S1PR1 and S1PR3 (required
for egress into the blood). The expression of each of these molecules was then related to anatomical location and
histological subtype.
Results: The expression of motility/adhesion molecules varied widely between individual patient samples and
correlated much more strongly with anatomical location than with histological subtype. SLO lymphomas
[comprising 10 follicular lymphoma (FL), 8 diffuse large B-cell lymphoma (DLBCL), 4 mantle-cell lymphoma (MCL)
and 5 marginal-zone lymphoma (MZL)] were characterised by pronounced over-expression of S1PR2, suggesting
that the malignant cells in these lymphomas are actively retained at the site of clonal expansion. In contrast, the
malignant B cells in ocular adnexal lymphomas (10 FL, 9 DLBCL, 4 MCL and 28 MZL) expressed a profile of
molecules suggesting a dynamic process of trafficking involving not only tissue retention but also egress via
S1PR3 and homing back to extranodal sites via CXCR4/CXCL12 and α4. Finally, leukaemic lymphomas (6 FL, 5
MCL and 2 MZL) were characterised by aberrant expression of the egress receptor S1PR1 and low expression of
molecules required for tissue entry/retention.
Conclusions: In summary, our study strongly suggests that anatomical location in B-NHL is governed by the
differential expression of specific adhesion/motility molecules. This novel observation has important implications
for therapeutic strategies that aim to disrupt protective micro-environmental interactions.
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Lymphocytes are motile cells owing to their pivotal role
in immune surveillance. They traffic through the im-
mune system in search of the specific antigen that binds
to their unique antigen receptor. However, the lympho-
cytes of B-cell non-Hodgkin’s lymphomas (B-NHL) tend
to arise and become lodged within tissues [1] and in this
way differ from their normal counterparts. The mecha-
nisms underlying the homing and accumulation of
lymphoma cells in secondary lymphoid organs (SLO)
(i.e. lymph nodes (LN) and the spleen) and extranodal
sites are not known. Since the tissue microenvironment
provides growth and survival stimuli for both normal
[2-4] and neoplastic lymphocytes [5-7], understanding
the mechanisms involved in the tissue residency of the
neoplastic lymphocytes in B-NHL could lead to new
therapeutic approaches.
We hypothesised that the trafficking and tissue localisa-
tion of lymphoma cells are governed by the expression of
molecules responsible for the homing of normal lympho-
cytes, i.e. chemokines, chemokine and sphingosine-1-
phosphate (S1P) receptors, and integrins. The chemokines
CXCL12 (SDF-1), CXCL13 (BLC), and CCL21 (SLC) pro-
mote entry of B cells into tissues by binding to theirFigure 1 The role of adhesion molecules, chemokines and S1P in lymp
nodes via high endothelial venules (HEVs) is achieved through a multis
transmigration. (B). Movement towards the chemokine CCL21 into nod
HEV. (C) Once in the node B cells move in the direction of the highest
the nodes is dependent on the chemokine CXCL13 and/or α4β1. The d
within the lymph node go on a ‘random walk’ visiting the B and T cell
through the lymphatic sinuses in a S1PR1 dependent manner independrespective receptors CXCR4, CXCR5 (BCA-1) and CCR7
[3,8,9]. In addition to its role in tissue entry, CXCL13 di-
rects B cells into the primary and secondary follicles of
LN (Figure 1) and the spleen [10,11]. Chemokines also ac-
tivate adhesion molecules, which facilitate the trafficking
of lymphocytes into and within tissues. The lymphocyte
integrins, αLβ2 (LFA-1) and α4β1 (VLA-4), bind to their
respective ligands on vascular endothelium and are im-
portant for transendothelial migration into LN (Figure 1)
and extranodal tissues, respectively [10,12,13]. In addition,
α4β1 mediates adhesion to fibronectin, which is involved
in the trafficking and adhesion of lymphocytes within tis-
sues [14,15].
Regarding the exit (egress) of lymphocytes from the LN
and spleen, this process is controlled by S1PR1 (Figure 1)
and S1PR3, respectively [16,17]. In contrast, S1PR2 has an
inhibitory role within lymphoid organs, preventing B-cells
from responding to chemokine signalling within the follicu-
lar region [18], resulting in their retention in the germinal
centre (GC) [19]. The importance of S1PR2 in lymphoma
is underlined by the fact that the gene is mutated in ap-
proximately 25% of cases of diffuse large B cell lymphoma
(DLBCL) [20]. Furthermore, about 50% of mice with tar-
geted disruption of S1PR2 develop lymphoma [21].hocyte entry, egress and retention. (A) B-cell migration into lymph
tep adhesion process involving rolling, sticking, crawling and finally
es is dependent on the integrin αLβ2 binding to ICAM-1 on the
concentration of chemokine/S1P. Movement towards the B zone of
irection of movement is shown here as a linear track, however cells
zones multiple times in the search for antigen before exiting
ently of integrin engagement.
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been examined in some types of lymphoma [13,22-24],
present knowledge is incomplete and difficult to compre-
hend, as chemokine/S1P receptors and integrins act to-
gether in a co-ordinated way to determine lymphocyte
localisation and trafficking. We therefore conducted a
comprehensive and systematic analysis of relevant chemo-
kine receptors, S1PRs and integrins in B-NHLs affecting
different anatomical sites, exploiting the fact that, al-
though most B-NHL occur within SLO [25], up to 25%
occur at extranodal sites [26,27], such as the ocular ad-
nexa [12], and in the blood [1]. By applying a combination
of immunohistochemical and flow cytometric approaches
to B-NHL located in SLO, ocular adnexae and blood (leu-
kaemic lymphomas), we found that B-NHL in the three
different tissue compartments expressed distinct patterns
of lymphocyte homing molecules, which could explain
their tissue localisation.
Results and discussion
Relationship between anatomical location and lymphoma
subtype
In order to relate the expression of molecules involved
in lymphocyte adhesion and migration to the anatomical
location and lymphoma subtype, it was first important
to understand the relationship between the latter two
variables within the cohort of patients selected for this
study. As is shown in Additional file 1: Table S1, among
the 27 lymphomas cases of the SLO, twice as many had
a diagnosis of FL (10) or DLBCL (8) than of MZL (5) or
MCL (4). In contrast, amongst the 51 OAL, more than
half were EMZL (28), with FL (10) and DLBCL (9) ac-
counting for most of the remaining cases, while the ma-
jority of the 13 leukaemic lymphomas were either FL (6)
or MCL (5). Looking at the relationship between the
lymphoma subtype and the anatomical location the
other way round, among cases of FL or MCL, the pro-
portion with SLO, ocular adnexal or blood involvement
was similar (10 versus 10 versus 6 and 4 versus 4 versus
5, respectively). In contrast, whilst DLBCL occurred with
similar frequency in the SLO or ocular adnexa (8 versus
9, respectively), it rarely involved the blood. For MZL,
80% of the 35 cases presented as OAL. The positive asso-
ciation between MZL and OAL and negative association
between DLBCL and leukaemic lymphoma reached statis-
tical significance (P < 0.001), whereas a weaker association
was evident between MCL and leukaemic presentation in
this cohort.
Expression of molecules involved in entry of lymphocytes
into LN
In order to elucidate the mechanisms responsible for the
preferential localisation of lymphomas at different ana-
tomical sites, we first analysed the molecules involved inthe entry of lymphocytes into LN, namely CCR7, its lig-
and CCL21 and the integrin αLβ2. The cases were
initially grouped according to anatomical location irre-
spective of lymphoma subtype (Figures 2 and 3A;
Table 1A). CCR7 was expressed at low levels in lymph-
omas affecting the SLO, ocular adnexae and blood, the
highest expression being observed in leukaemic lymph-
omas (P < 0.001). In contrast, CCL21 was expressed at
much higher levels in lymphomas affecting the SLO
compared to OAL (P < 0.001), thereby providing greater
potential for receptor-ligand interaction and, conse-
quently, tissue entry. αL was expressed by lymphomas
affecting all three anatomical sites but at different levels,
being highest in OAL (P < 0.001) and lowest in leu-
kaemic lymphomas (P < 0.001). Comparison between in-
dividual lymphoma entities irrespective of anatomical
location (Figure 3B; Table 1B) showed that the expres-
sion of CCR7, CCL21 and αL was remarkably constant,
although levels of αL were higher in MZL than MCL, in
keeping their respective associations with OAL and leu-
kaemic lymphoma.
Statistically significant differences in the expression of
CCR7, CCL21 and αL were not observed when lymph-
omas were compared by anatomical site within each
histological subtype, or when they were compared by
subtype within each anatomical site (Additional file 2:
Figure S1 and 2A). However, the small number of cases
in some of the groups precludes firm conclusions from
being drawn. Analysis of different anatomical variants of
OAL showed no association between CCR7, CCL21 or
αL expression and location in the eyelid, conjunctiva or
orbit (Additional file 2: Figure S2B).Expression of molecules involved in entry into extranodal
sites
We next analysed the molecules involved in the entry of
lymphocytes into extranodal tissues, namely CXCR4,
CXCL12 and α4 integrin. Grouping cases according to
anatomical location (Figures 2 and 4A, Table 1A)
showed that CXCR4 and α4 were expressed at signifi-
cantly higher levels in OAL compared to lymphomas af-
fecting the SLO or blood, indicating a greater potential
for migration into extranodal sites. Furthermore,
CXCL12 was present at higher levels in OAL compared
to lymphomas of the SLO, thereby providing a stronger
homing signal for CXCR4-expressing cells. Leukaemic
lymphomas expressed particularly low levels of both
CXCR4 and α4. Comparison between individual lymph-
oma subtype irrespective of anatomical location (Figure 4B
and Additional file 2: Figure S3A; Table 1B) revealed
no significant differences in the expression of any of
these molecules, although there was a trend towards
higher CXCR4 expression in MZL and lower CXCL12
Figure 2 Representative cases of SLO and OAL showing different expression of molecules involved in lymphocyte homing. TMA cores for CCL21,
S1PR2 and S1PR3 from MCL; CXCR4, CXCL12 and α4 are from DLBCL. (Other histological types are shown in Additional file 2: Figure S1). Bar = 60 μM.
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associations with OAL and leukaemic lymphoma.
Statistically significant differences in the expression of
CXCR4, CXCL12 and α4 were not observed when
lymphomas were compared by anatomical site within
each histological subtype, or when they were compared
by subtype within each anatomical site (Additional file 2:
Figure S3A). However, the small number of cases in
some of the groups precludes firm conclusions from be-
ing drawn. Analysis of anatomical variants of OAL
showed that CXCL12 was expressed at higher levels incases located in the eyelid as opposed to the conjunctiva
or orbit (p < 0.014) (Additional file 2: Figure S3B).
Expression of molecules involved in retention within
tissues
Having analysed the molecules involved in the entry of
lymphocytes into tissues, we next turned our attention
to factors involved primarily in retention within tis-
sues, i.e. CXCR5, CXCL13 and S1PR2. Grouping
lymphomas according to anatomical location (Figure 2










Figure 3 Expression of molecules involved in entry into SLO. A. Box and whiskers plots show lymphomas analysed according by tissue of origin.
B. Box and whiskers plots show lymphomas according to histology. Statistically significant differences in expression are shown.
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ocular adnexae (P < 0.001) than in leukaemic lymph-
omas (P < 0.001). CXCL13 was also expressed, albeit at
low levels, in ocular adnexal and SLO lymphomas, ex-
pression being higher in OAL (P < 0.001). Of particular
note, S1PR2 was expressed at very high levels in lymph-
omas of the SLO but was virtually absent in OAL (P <
0.001) and leukaemic lymphomas (P < 0.001). ThisTable 1 Expression of molecules involved in lymphocyte traff
A. Anatomical sites
Lymphoma subtype Entry into SLO Entry into extranod
CCR7 CCL21 αL CXCR4 CXCL1
SLO ± +++ + ++ ±
OAL ± + +++ +++ +
LL + ± ±
B. Histological features
Lymphoma subtype Entry into SLO Entry into extranod
CCR7 CCL21 αL CXCR4 CXCL1
FL ± +++ + + +
MZL ± +++ ++ +++ +
DLBCL ± +++ + ++ +
MCL ± +++ ± ++ -
Expression is based on the median staining scores: 0–1 (−); >1-2 (±); >2-4 (+); >4-6
lymphoma; LL - leukaemic lymphoma; NA - not available.profile of CXCR5, CXCL13 and S1PR2 expression
strongly suggests that the malignant B-cells in lymph-
omas of the SLO (and to a lesser extent OAL) are ac-
tively retained in the tissues, whereas the malignant
cells in leukaemic lymphoma are allowed unimpeded
passage through the tissues and back into the blood.
Comparison between individual histological subtypes ir-
respective of anatomical location (Figure 5B; Table 1B)icking
al tissues Retention in tissues Egress
2 α4 CXCR5 CXCL13 S1PR2 S1PR1 S1PR3
+ ++ ± +++ ± +
+++ +++ + - ± ++
± ± - +++ NA
al tissues Retention in tissues Egress
2 α4 CXCR5 CXCL13 S1PR2 S1PR1 S1PR3*
++ ++ + ± ± +
++ ++ + - + +
++ +++ + ++ - +
++ ++ + ± ++ +








Figure 4 Expression of molecules involved in entry into extranodal sites. A. Box and whiskers plots show lymphomas analysed according by tissue of
origin. B. Box and whiskers plots show lymphomas according to histology. Statistically significant differences in expression are shown.
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CXCL13. However, levels of CXCR5 were highest in
DLBCL in keeping with its negative association with
leukaemic lymphoma, whereas S1PR2 expression was
lowest in MZL in keeping with the fact that only a mi-
nority of these cases affected the SLO.
Statistically significant differences in the expression of
CXCR5, CXCL13 and S1PR2 were not observed when
lymphomas were compared by anatomical site within
each histological subtype (Additional file 2: Figure S4A).
However, the small number of cases in some of the
groups precludes firm conclusions from being drawn.
Comparing cases by histological subtype within each
anatomical site showed differences in CXCR5 and
S1PR2 expression among lymphomas of the SLO only.
Specifically, CXCR5 expression was highest in nodal
DLBCL and lowest in MZL (Additional file 2: Figure
S4A). These findings were in keeping with those in the
overall cohort.
Analysis of anatomical variants of OAL indicated that
there were no significant differences in the expression
of CXCR5, CXCL13 and S1PR2 between lymphomas
located in the orbit, conjunctiva or lid (Additional file 2:
Figure S4B).Expression of molecules involved in egress from tissues
Finally, we analysed the egress receptors S1PR1 and
S1PR3. Grouping lymphomas according to anatomical
location (Figures 2 and 6A, Table 1A) revealed that
S1PR1 was expressed at much higher levels in leukaemic
lymphomas compared to OAL and lymphomas of the
SLO. This result was unexpected given that S1PR1 is
expressed at low levels in normal lymphocytes as a re-
sult of rapid internalisation of the receptor following
binding to its ligand, which is present at high levels in
the blood [28]. Technical problems with the antibody
precluded flow cytometric analysis of S1PR3 in leu-
kaemic lymphomas. However, S1PR3 was expressed at
higher levels in OAL compared to lymphomas of the
SLO. Comparison between histological subtype irre-
spective of anatomical location (Figure 6B; Table 1B) re-
vealed mostly similar expression of S1PR1 and S1PR3
among the different lymphoma subtypes, although
S1PR1 was expressed at low levels in DLBCL in keeping
with its negative association with leukaemic lymphoma.
Statistically significant differences in the expression of
S1PR1 and S1PR3 were not observed when lymphomas
were compared by anatomical site within each histo-













Figure 5 Expression of molecules involved in retention within LN. A. Box and whiskers plots show lymphomas analysed according by tissue of
origin and B. Box and whiskers plots show lymphomas according to histology. Statistically significant differences in expression are shown.
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the small number of cases in some of the groups pre-
cludes firm conclusions from being drawn.
Analysis of anatomical variants of OAL indicated that
there were no significant differences in the expression of
S1PR1 or S1PR3 between lymphomas located in the
orbit, conjunctiva or lid (Additional file 2: Figure S5B).Overall correlation between anatomical location and
expression of molecules involved in lymphocyte
trafficking
The expression of most of the motility and adhesion
molecules examined in this study varied widely between
cases and correlated much more strongly with anatom-
ical location than with lymphoma histology. Further-
more, where expression did correlate with lymphoma
histology, this reflected an association between the spe-
cific histological entity and a particular anatomical loca-
tion. For example, the expression profile of MZL could
be explained by the association between MZL and OAL,
whereas that of DLBCL could be explained by the nega-
tive association between DLBCL and leukaemic lymph-
oma. These observations indicate that the adhesion/
motility molecules expressed in B-NHL are a feature of
anatomical location rather than lymphoma histology.Potential explanation for the anatomical location of SLO
lymphomas
Our study also provides compelling evidence that the
motility and adhesion molecules expressed by different
B-NHL are responsible for their different anatomical lo-
cations. In the case of lymphomas located in the SLO,
our findings indicate that the neoplastic B cells may have
difficulty in exiting from the tissues because they express
relatively low levels of the egress receptors S1PR1 and
S1PR3. Furthermore, the high expression of CXCR5 and
S1PR2 by these cells should result in their active reten-
tion at the site of clonal expansion. Our demonstration
that high CXCR5 expression is a feature of all types of
lymphomas of the SLO, including nodal DLBCL, is in
keeping with, and adds to, previous reports document-
ing high CXCR5 expression in FL, MCL and MZL
[24,29,30], all of which frequently involve either the LN
or the spleen. However, the relatively low tissue expres-
sion of CXCL13 in lymphomas of the SLO calls into
question the functional significance of high CXCR5 ex-
pression and suggests that S1PR2 over-expression may
play a dominant role in mediating tissue retention given
the ubiquitous presence of its ligand in the blood and
lymph. In addition to S1PR2-mediated tissue retention,
the high levels of CCL21 expressed in lymphomas of the











Figure 6 Expression of molecules involved in egress from tissues. A. Box and whiskers plots show lymphomas analysed according to
histology and A. Lymphomas analysed according by tissue of origin. B. Box and whiskers plots show lymphomas according to histology.
Statistically significant differences in expression are shown.
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relatively low expression of αL in lymphomas of the SLO
calls into question their ability to enter LNs effectively [31].
Taken together, therefore, the profile of motility and adhe-
sion molecules expressed in lymphomas of the SLO sug-
gests that the malignant cells are actively retained at the
site of clonal expansion primarily due to high expression of
S1PR2. This striking and unique feature of nodal and
splenic lymphomas was not expected as mutations in the
gene encoding S1PR2 have been reported in a significant
proportion of patients with nodal DLBCL, and generally re-
sult in reduced expression of the receptor [20]. Further in-
vestigation of this apparent anomaly is required but was
beyond the scope of the present study.
Potential explanation for the anatomical location of OAL
The expression profile of motility and adhesion molecules
in OAL was quite different from that in lymphomas of theSLO, and included high expression of α4 and CXCR4 to-
gether with significant levels of CXCL12. This combination
of features should favour the entry of neoplastic B-cells cells
into extranodal sites since α4β1 is essential for migration
across the endothelium of small veins towards the sites of
inflammation [32], while CXCR4 has been implicated in
the dissemination of many malignancies to multiple differ-
ent tissues [33,34]. 7Interestingly, OAL cells also expressed
high levels of αL, which is involved in entry into LN. How-
ever, OALs expressed CCR7 at very low levels, calling into
question their ability to migrate into tissues expressing
CCL21. In common with lymphomas of the SLO, OALs
expressed high levels of CXCR5. They also expressed de-
tectable levels of CXCL13, suggesting the potential for
ligand-receptor interactions favouring tissue retention.
With regard to S1P receptors, OAL cells did not express
significant levels of S1PR2 or S1PR1 but did express high
levels of S1PR3 suggesting that these cells have the
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findings suggest that the malignant cells in OAL likely
undergo a dynamic process of trafficking involving
egress into the blood (directed by S1PR3) and homing
back to the extranodal tissues (directed by CXCR4/
CXCL12 and mediated by α4) where an element of re-
tention may occur (via CXCR5/CXCL13). This concept
is entirely in keeping with the fact that OAL are fre-
quently bilateral [35] and that extranodal lymphomas
often progress to involve multiple extranodal tissues,
including not only the conjunctiva but also lacrimal
glands, salivary glands, stomach, lung, thyroid gland
and skin [26,27]. The initial confinement of many cases
of extranodal lymphoma to a single anatomical site is
possibly explained by their evolution on a background
of site-specific chronic inflammation. For example,
OAL can be associated with underlying autoimmune
disease (e.g. Sjogren’s syndrome) [35] and, in some geo-
graphical areas, Chamydia psittaci infections [35,36].
However, once established, extranodal lymphomas are
likely to acquire the potential to disseminate to mul-
tiple sites owing to their trafficking properties.
Potential explanation for the anatomical location of
leukaemic lymphomas
In addition to explaining the anatomical location of tissue-
based lymphomas, our study also helps to explain why
some cases of B-NHL present with leukaemia. Thus, the
neoplastic B cells from patients with leukaemic lymphoma
expressed low or insignificant levels of molecules required
for entry into SLO (CCR7, αL), entry into extranodal tissues
(CXCR4, α4) and tissue retention (CXCR5, S1PR2). In con-
trast, they expressed very high levels of the egress receptor
S1PR1. This expression profile strongly favours egress over
tissue entry/retention and provides a plausible explanation
for the accumulation of the malignant cells in the blood. It
is noteworthy that the expression all of these molecules in
leukaemic lymphomas differs from their expression in nor-
mal blood B cells [37-40]. Thus S1PR1 is not found on cir-
culating normal B cells due to the abundance of its ligand,
S1P, in plasma resulting in receptor internalisation [28]. Al-
though we did not measure S1P in the blood, there are no
reports in the literature of levels of this ubiquitous
glycolipid being reduced in any disease state. Therefore, the
high expression of S1PR1 on the neoplastic B cells of leu-
kaemic lymphomas can be regarded as aberrant. The same
consideration applies to the low expression of CXCR5,
since normal circulating B cells express high levels of
this receptor [41]. Elucidating the mechanisms responsible
for the aberrant over-expression of S1PR1 and under-
expression of CXCR5 in leukaemic lymphomas was beyond
the scope of the present study but is the subject of ongoing
investigation. The low expression of α4 on leukaemic
lymphomas is also at odds with its ubiquitous expressionon normal B cells but is in keeping with its frequent ab-
sence in chronic lymphocytic leukaemia [31].
Conclusion
The development and progression of B-NHL is known to
depend on interactions with the tumour microenvironment
that are mediated/directed by chemokines, chemokine re-
ceptors and integrins [42]. Consequently, by elucidating the
molecules and likely processes responsible for the location
of lymphomas at different anatomical sites, our study has
implications for both existing and emerging therapies. The
protective effect of the microenvironment in the context of
existing treatments is illustrated by a recent report on fol-
licular lymphoma, which traced the clones responsible for
relapse following chemotherapy. These clones had the same
genetic fingerprint as the original clone and had been able
to survive in the tissues during clinical remission [43]. With
regard to emerging therapies, drugs such as ibrutinib and
idelalisib, which inhibit kinases involved in B-cell receptor
signalling, have successfully been used in the treatment of
lymphoma [44-46]. One of the striking effects of these
drugs is displacement of malignant B cells from their pro-
tective environmental niches, and available evidence sug-
gests that this effect results at least in part from blockade of
chemokine-induced adhesion signals [47]. Our study sug-
gests that a similar effect might be achieved through the
targeted blockade of specific chemokine receptors. In keep-
ing with this concept, inhibitors of CXCR4 [48] or CXCR5
[49] have recently been shown to enhance the efficacy of ri-
tuximab therapy in a mouse model of B-NHL.
In summary, our study constitutes the first systematic
attempt to explain why malignant lymphocytes in B-NHL
accumulate at different anatomical sites. We showed that
most of the key molecules involved in the trafficking of
normal lymphocytes are variably expressed and that their
pattern of expression can explain the differential anatom-
ical location of lymphomas in SLO, ocular adnexae and
blood. In making these observations, our study indicates
possible new approaches to therapy based on disrupting




All samples used for this study were obtained with in-
formed consent. Formalin fixed, paraffin embedded tissue
samples were obtained from 27 patients with lymphomas
of SLO [10 follicular lymphoma (FL), 8 DLBCL, 4 mantle-
cell lymphoma (MCL), 3 splenic marginal-zone lymphoma
(SMZL) and 2 nodal MZL] and 51 patients with ocular ad-
nexa lymphomas (OAL). The 51 OAL comprised 28 extra-
nodal marginal zone B-cell lymphomas (EMZL), 10 FL, 9
DLBCL, and 4 MCL. Cryopreserved mononuclear cells
were obtained from 13 patients with B-NHL who
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MZL). Clinical data linked to the lymphoma samples are
shown in Additional file 1: Table S2.Tissue microarray (TMA) construction
Tissue cores of 0.6 mm diameter and were assembled into
microarrays using the Manual Tissue Arrayer MTA-1
(Beecher instruments, WI, USA). Two to three cores from
each donor tissue block were used. Colon, kidney and tonsil
cores were incorporated into the TMA as control tissues.
Antibodies
The following monoclonal antibodies were used: CXCR4,
CXCL13, CCL21, S1PR3 and αL (Abcam, Cambridge,
UK); CXCR5, CXCL12 (R&D Systems, Oxford, UK);
CCR7 (Novus Biologicals, Cambridge, UK); S1PR1, α4
(Santa Cruz, Middlesex, UK); S1PR2 (Sigma, Poole, UK).
Mouse IgG1 and rabbit Ig were used as negative controls
(R&D Systems, Abingdon, UK). All antibodies were ti-
trated on normal tissues and used at saturating concentra-
tions (Additional file 1: Table S3).
Antigen detection and measurement
Immunohistochemical staining
The EnVision™ staining method was used. As previously
described, de-waxing of the sections and antigen retrieval
were performed with EnVision™ FLEX target retrieval
solution with the Dako PT-link module [50]. Slides were
stained with an autostainer using the EnVision™ FLEX
convenience kit (Dako, Cambridgeshire). Slides were
counterstained in Meyers’ haematoxylin (Sigma).
TMA scoring
A standardised scoring method was used based on the
percentage of lymphocytes showing any staining com-
bined with the staining intensity [50]. A minimum of two
cores from each tissue block were independently scored
by at least two researchers (SM, KJT, SEC). The scores for
the percentage of positive lymphocytes were as follows:
none (0), 1-24% (1), 25-49% (2), 50-74% (3) and 75-100%
(4). The intensity of the stained lymphocytes was scored
as weak (1), moderate (2) or strong (3). Multiplying the
percentage of stained lymphocytes by the staining inten-
sity gave a protein expression score ranging from 0 (nega-
tive) to 12 (highest).
Flow cytometry
Blood lymphocytes were stained using an indirect immuno-
fluorescence technique. Lymphoma B cells were identified
by co-staining with CD19-PerCP-Cy5.5 (Becton Dickinson).
The percentage and mean fluorescence intensity (MFI) were
determined on CD19+ cells. The results were converted intoa score as for the TMAs [for MFI [0–5 (0), 5–10 (1), 10–90
(2), >90 (3)].
Statistical analysis
The distribution of chemokines and their receptors was
first examined for normality using histograms and nor-
mal Q-Q plots. Where there was obvious deviation from
normality, logarithm or square root transformations
were applied.
For data that could be approximated using a normal
distribution, family-wise comparison was carried out
using one-way ANOVA. Where statistical significance
was suggested at the 0.05 level, post-hoc pair-wise com-
parisons were carried out using the Tukey test.
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